Bellicum Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview
13/05/2022 15:03
* Bellicum Pharmaceuticals Inc BLCM.OQ BLCM.O is
expected
to report results on August 10 (estimated).
* Refinitiv's mean analyst estimate for Bellicum
Pharmaceuticals
Inc is for a loss of 70 cents per share. For the same quarter
last year, the company reported a loss of 22 cents per share.
* The one available analyst rating on the shares is "strong
buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Strong Buy".
* Wall Street's median 12-month price target for Bellicum
Pharmaceuticals Inc is $5, above its last closing price
of $1.43.
This summary was machine generated May 13 at 14:03 GMT. All
figures in US dollars unless otherwise stated
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview